U.S. Healthcare

TIGLUTIK® (riluzole) is the Only Formulation of Riluzole Indicated for Both Oral and PEG Tube Administration.

How to Order
Your Patients

How to Order TIGLUTIK®
for Your Patients

TIGLUTIK Was Developed to Meet the Needs of People with ALS

Bottle of Tiglutik (riluzole) with syringe

TIGLUTIK is the only formulation of riluzole approved by the FDA for both oral and PEG tube use1. TIGLUTIK is an oral suspension. One dose of TIGLUTIK 50 mg (10 mL) is bioequivalent to one RILUTEK® (riluzole) 50 mg tablet and it is taken twice a day, every 12 hours.1-3

Based on the standards developed by the International Dysphagia Diet Standardization Initiative (IDDSI), TIGLUTIK has a mildly thick consistency (IDDSI criteria Level 2),3,4  and it is easy for patients to swallow or administer in a PEG tube.  TIGLUTIK is approved for use throughout all stages of ALS1. Patients can start taking TIGLUTIK as soon as they are diagnosed with ALS.

Click here for information to How to Order TIGLUTIK for Your Patients to ensure your patients with ALS get the full dose of riluzole they deserve.

  1. TIGLUTIK® (riluzole) [package insert]. Berwyn, PA: ITF Pharma; March 2020.
  2. Rilutek (riluzole) [package insert]. Cary, NC: Covis Pharmaceuticals, Inc.; July 2016.
  3. Data on file. ITF Pharma. Berwyn, PA; December 2019.
  4. International Dysphagia Diet Standardisation Initiative. https://iddsi.org/. Accessed July 1, 2020.


TIGLUTIK is indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS).

Important Safety Information


TIGLUTIK is contraindicated in patients with a history of severe hypersensitivity reactions to riluzole or to any of its components.

Warnings and Precautions

TIGLUTIK can cause liver injury and there have been cases of drug-induced liver injury, some of which were fatal, in patients taking riluzole. Asymptomatic elevations of hepatic transaminases have been reported and, in some patients, have recurred upon re-challenge with riluzole. Maximum increases in ALT occurred within 3 months after starting riluzole. Monitor patients for hepatic injury every month for the first 3 months of treatment, and periodically thereafter; TIGLUTIK should be discontinued if there is evidence of liver dysfunction, for example, elevated bilirubin. Use of TIGLUTIK with other hepatotoxic drugs may increase the risk for hepatotoxicity.

TIGLUTIK can cause neutropenia. Cases of severe neutropenia (absolute neutrophil count less than 500 per mm3) within the first 2 months of riluzole treatment have been reported. Advise patients to report febrile illnesses.

TIGLUTIK can cause interstitial lung disease, including hypersensitivity pneumonitis. Discontinue TIGLUTIK immediately if interstitial lung disease develops.

Adverse Reactions

The most common adverse reactions (incidence greater than or equal to 5% and greater than placebo) of TIGLUTIK were oral hypoesthesia (29%), asthenia (19%), nausea (16%), decreased lung function (10%), hypertension (5%), and abdominal pain (5%).

Coadministration of TIGLUTIK with strong or moderate CYP1A2 inhibitors, such as ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, and zileuton, may increase the risk of TIGLUTIK-associated adverse reactions. 

Coadministration of TIGLUTIK with CYP1A2 inducers may result in decreased efficacy of TIGLUTIK.

Use in Specific Populations

Patients with mild or moderate hepatic impairment (Child-Pugh’s score A or B) had increases in AUC compared to patients with normal hepatic function. Thus, patients with mild or moderate hepatic impairment may be at increased risk of adverse reactions. Use of TIGLUTIK is not recommended in patients with baseline elevations of serum aminotransferases greater than 5 times the upper limit of normal or evidence of liver dysfunction.

Japanese patients are more likely to have higher riluzole concentrations, and thus may be at a greater risk of adverse reactions.

Please see accompanying prescribing information.

Intended for U.S. Residents Only

ITF Pharma logo

©2021 ITF Pharma Inc. All rights reserved.  TIGLUTIK is a trademark of ITALFARMACO SA 

3 Paoli Plaza, Suite C
Paoli, PA 19301 United States
Medical/Product Inquiries: 844-763-1198
EDW Pharma US Headquarters: 610-937-6172